BBI Group, which offers products and services to the diagnstic, healthcare, research, defence and food industries, has announced a £14m investment to boost capacity and long term growth. The announcement takes the company’s overall investment to approximately £20m across 2016 and 2017.
The plans – supported by a £1.8m grant from the Welsh Government – will see BBI Group move to a new 120,000sqft headquarters at Crumlin, Caerphilly with easy access to the M4 corridor and Cardiff International Airport.
The investment will aim to consolidate BBI’s existing operations in Blaenavon, Cardiff and Dundee, providing improved manufacturing and enzyme production facilities to serve the global diagnostics and healthcare market place.
CEO Lyn Rees said: “The investment will give us the pedigree to compete more effectively in our expanding markets in Europe, USA and China.”
“We will develop our products in an enhanced cleanroom environment and to the highest European and US regulatory standards.”
With Welsh Government and local authority backing, the investment also aims to create around 50 new positions up to 2020. This will provide career opportunities in the South Wales Valleys region and foster closer links to the scientific and academic community.
Economy Cabinet Secretary Ken Skates said: “This will not only create and safeguard a significant number of high quality jobs, but will also support the local economy through an annual spend of more than £1m with supply chain companies.”
“BBI Group is a made-in-Wales success story; a highly successful company and a strategically important player in the life science sector globally.”
As part of the £14 million investment package, the company will upgrade its Sittingbourne manufacturing operation, which provides cell culture products, proteins and antibodies to clients across the world.
